Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Inside the Ben Johnson hiring: What convinced him Chicago Bears are ‘set up for success’ — and how they were ‘ready to pounce’
The interview was scheduled for Jan. 11. The Detroit Lions were deep into their postseason bye week and still awaiting their ...
Johnson & Johnson price target lowered to $155 from $170 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.